Marqeta Inc vs Relay Therapeutics Inc. Common Stock — how do they compare? Marqeta Inc trades at $17.36 (market cap $1.78B), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 2.2× Marqeta Inc's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| MQ | RLAY | |
|---|---|---|
Market Cap | $1.78B | $3.94B |
Volume | 1,087,097 | 3,432,928 |
Sector | Technology | Health |
52-Week High | $20.32 | $20.75 |
52-Week Low | $15.04 | $6.03 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $1.09B | $3.06B |
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $17.44, up 5.38% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with three consecutive quarterly EPS beats and positive cash flow trends, though valuation remains elevated with a P/E of 189.56. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic growth initiatives.
While technical indicators suggest near-term strength, the stock faces fundamental challenges with negative net income and high valuation multiples. Analyst consensus is cautious with a $11.38 price target below current levels, indicating 31.82% buy ratings. Key risks include contract renewals in Q3 2026 and growth moderation expectations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →